Iom.edu: August 22, 2012.
Advances in technologies and knowledge are creating new avenues for research and opportunities for the discovery and clinical development of innovative therapies and diagnostics. However, despite these opportunities, only a small fraction of investigational products are successfully developed into cures and therapies that can be accessed by patients. One response to the ever-widening gap between the number and promise of basic scientific discoveries and the translation of those discoveries into therapies is a renewed emphasis on collaborative approaches among federal agencies, academia, and industry, all directed at the advancement of the drug development enterprise.
The newly developed Cures Acceleration Network (CAN) — a part of the National Center for Advancing Translational Sciences (NCATS) within the National Institutes of Health (NIH) — has the potential to catalyze widespread changes in NCATS, NIH, and the drug development ecosystem in general. Read more